TY - JOUR
T1 - Unraveling the Endocannabinoid System
T2 - Exploring Its Therapeutic Potential in Autism Spectrum Disorder
AU - Jana, Ankit
AU - Nath, Arnab
AU - Sen, Palash
AU - Kundu, Swikriti
AU - Alghamdi, Badrah S.
AU - Abujamel, Turki S.
AU - Saboor, Muhammad
AU - Woon-Khiong, Chan
AU - Alexiou, Athanasios
AU - Papadakis, Marios
AU - Alam, Mohammad Zubair
AU - Ashraf, Ghulam Md
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12
Y1 - 2024/12
N2 - The salient features of autism spectrum disorder (ASD) encompass persistent difficulties in social communication, as well as the presence of restricted and repetitive facets of behavior, hobbies, or pursuits, which are often accompanied with cognitive limitations. Over the past few decades, a sizable number of studies have been conducted to enhance our understanding of the pathophysiology of ASD. Preclinical rat models have proven to be extremely valuable in simulating and analyzing the roles of a wide range of established environmental and genetic factors. Recent research has also demonstrated the significant involvement of the endocannabinoid system (ECS) in the pathogenesis of several neuropsychiatric diseases, including ASD. In fact, the ECS has the potential to regulate a multitude of metabolic and cellular pathways associated with autism, including the immune system. Moreover, the ECS has emerged as a promising target for intervention with high predictive validity. Particularly noteworthy are resent preclinical studies in rodents, which describe the onset of ASD-like symptoms after various genetic or pharmacological interventions targeting the ECS, providing encouraging evidence for further exploration in this area.
AB - The salient features of autism spectrum disorder (ASD) encompass persistent difficulties in social communication, as well as the presence of restricted and repetitive facets of behavior, hobbies, or pursuits, which are often accompanied with cognitive limitations. Over the past few decades, a sizable number of studies have been conducted to enhance our understanding of the pathophysiology of ASD. Preclinical rat models have proven to be extremely valuable in simulating and analyzing the roles of a wide range of established environmental and genetic factors. Recent research has also demonstrated the significant involvement of the endocannabinoid system (ECS) in the pathogenesis of several neuropsychiatric diseases, including ASD. In fact, the ECS has the potential to regulate a multitude of metabolic and cellular pathways associated with autism, including the immune system. Moreover, the ECS has emerged as a promising target for intervention with high predictive validity. Particularly noteworthy are resent preclinical studies in rodents, which describe the onset of ASD-like symptoms after various genetic or pharmacological interventions targeting the ECS, providing encouraging evidence for further exploration in this area.
KW - 2-Arachidonoylglycerol (2-AG)
KW - Anandamide (AEA)
KW - Autism spectrum disorder
KW - Endocannabinoid system
UR - http://www.scopus.com/inward/record.url?scp=85193035323&partnerID=8YFLogxK
U2 - 10.1007/s12017-024-08781-6
DO - 10.1007/s12017-024-08781-6
M3 - Review article
C2 - 38744725
AN - SCOPUS:85193035323
SN - 1535-1084
VL - 26
JO - NeuroMolecular Medicine
JF - NeuroMolecular Medicine
IS - 1
M1 - 20
ER -